Inspire Medical (INSP) entered into an accelerated share repurchase transaction under an agreement with Goldman Sachs to repurchase an aggregate of $75.0M of shares of the company’s common stock, par value 0.1c per share. The ASR transaction is being completed pursuant to a previously announced $150.0M share repurchase program authorized by the company’s Board of Directors. The ASR transaction is scheduled to terminate in Q1 2025. The share repurchase program will expire on August 5, 2026, subject to the earlier termination or extension by the Board, in its sole discretion and without prior notice, or until such time that the funds designated for the stock repurchase program are depleted.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target raised to $260 from $255 at Piper Sandler
- Inspire Medical price target raised to $252 from $240 at Baird
- Inspire Medical price target raised to $198 from $187 at Wells Fargo
- Inspire Medical Reports Strong Q3 Growth and Raises Outlook
- Inspire Medical Systems Sees Strong Q3 Growth in 2024